Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$1.96 USD
+0.14 (7.69%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $1.98 +0.02 (1.02%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Income Statements
Fiscal Year end for Esperion Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 116 | 75 | 78 | 228 | 148 |
Cost Of Goods | 43 | 27 | 14 | 2 | 0 |
Gross Profit | 73 | 49 | 64 | 225 | 148 |
Selling & Adminstrative & Depr. & Amort Expenses | 229 | 228 | 291 | 347 | 241 |
Income After Depreciation & Amortization | -156 | -180 | -227 | -121 | -93 |
Non-Operating Income | 5 | 3 | 4 | 1 | 4 |
Interest Expense | 59 | 57 | 46 | 23 | 8 |
Pretax Income | -209 | -234 | -269 | -144 | -97 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -209 | -234 | -269 | -144 | -97 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -209 | -234 | -269 | -144 | -97 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -154 | -177 | -224 | -119 | -93 |
Depreciation & Amortization (Cash Flow) | 1 | 2 | 2 | 2 | 0 |
Income After Depreciation & Amortization | -156 | -180 | -227 | -121 | -93 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 103.11 | 66.41 | 28.90 | 27.47 | 27.09 |
Diluted EPS Before Non-Recurring Items | -2.03 | -3.52 | -9.31 | -5.23 | -3.59 |
Diluted Net EPS (GAAP) | -2.03 | -3.52 | -9.31 | -5.23 | -3.59 |
Fiscal Year end for Esperion Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 73.83 | 137.74 | 32.25 | 33.97 | 25.79 |
Cost Of Goods | 15.61 | 10.08 | 11.45 | 13.38 | 6.79 |
Gross Profit | 58.23 | 127.66 | 20.80 | 20.59 | 19.00 |
SG&A, R&D, and Dept/Amort Expenses | 55.65 | 55.39 | 63.16 | 48.13 | 56.06 |
Income After SG&A, R&D, and Dept/Amort Expenses | 2.58 | 72.27 | -42.36 | -27.54 | -37.06 |
Non-Operating Income | -50.78 | 2.78 | 1.08 | 1.28 | 1.66 |
Interest Expense | 13.72 | 14.02 | 15.06 | 15.00 | 14.54 |
Pretax Income | -61.93 | 61.02 | -56.34 | -41.25 | -49.94 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -61.93 | 61.02 | -56.34 | -41.25 | -49.94 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -61.93 | 61.02 | -56.34 | -41.25 | -49.94 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 188.79 | 189.64 | 112.40 | 111.87 | 109.24 |
Diluted EPS Before Non-Recurring Items | -0.05 | 0.34 | -0.50 | -0.37 | -0.46 |
Diluted Net EPS (GAAP) | -0.33 | 0.34 | -0.41 | -0.37 | -0.46 |